Brassard, Maryse <br/><br/>
Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer.  [electronic resource] 

 -  The Journal of clinical endocrinology and metabolism  Sep 2011 
 - 2741-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1945-7197 
<br/><br/><label>Standard No.: </label>10.1210/jc.2010-2771  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma, Follicular--blood<br/>Adenocarcinoma, Papillary--blood<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Blood Glucose<br/>Calcium--blood<br/>Cross-Over Studies<br/>Enzyme Inhibitors--therapeutic use<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Parathyroid Hormone--blood<br/>Piperidines--therapeutic use<br/>Proto-Oncogene Proteins c-ret--antagonists & inhibitors<br/>Quinazolines--therapeutic use<br/>Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors<br/>Testosterone--blood<br/>Thyroid Neoplasms--drug therapy<br/>Treatment Outcome<br/>Vitamin D--blood